Dextromethorphan and guaifenesin use should be monitored carefully in people with "bad metabolizer" CYP2D6 enzyme stages and sufferers who are sedated. This combination medication features a big median harmful dose (TD50) to median productive dose (ED50) ratio (or therapeutic index) in these sufferers.If your medical professional directs you to